Takeda Pharmaceutical Company Ltd
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 366
- Registration Number
- NCT03469349
- Locations
- 🇰🇿
"National scientific centre of oncology and transplantology", Astana, Kazakhstan
🇷🇺SBHI of Ryazan region Regional clinical cardiological dispensary, vessel surgery department/ FSBI of Ryazan Region "Ryazan State Medical Univesity n.a. I.P. Pavlov" of MoH of Russia, Ryazan, Russian Federation
🇬🇪Center of Vascular and Heart Disease, Tbilisi, Georgia
A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA Tablet
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 276
- Registration Number
- NCT03456960
- Locations
- 🇯🇵
Fukuoka Mirai Hospital, Fukuoka, Japan
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 61
- Registration Number
- NCT03439293
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
🇺🇸Research Medical Center - Kansas City, Kansas City, Missouri, United States
A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 28
- Registration Number
- NCT03437564
- Locations
- 🇯🇵
Nishi Kumamoto Hospital, Kumamoto, Japan
A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT03434977
- Locations
- 🇯🇵
Fukuoka Mirai Hospital, Fukuoka, Japan
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 295
- Registration Number
- NCT03433001
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue
- Conditions
- Dengue Fever
- Interventions
- Biological: TAK-003Biological: Placebo
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 923
- Registration Number
- NCT03423173
- Locations
- 🇺🇸
Synexus Limited - Columbus, Columbus, Ohio, United States
🇺🇸Optimal Research, Rockville, Maryland, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
- Conditions
- Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT03420742
- Locations
- 🇫🇷
Hopital de la Timone, Marseille, Provence Alpes COTE D'azur, France
🇮🇹Policlinico Sant'Orsola Malpighi, Bologna, Italy
🇮🇹Ospedale San Raffaele, Milano, Italy
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 45
- Registration Number
- NCT03416374
- Locations
- 🇯🇵
Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵Kyorin University Hospital, Mitaka, Tokyo, Japan
🇯🇵Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 104
- Registration Number
- NCT03410108
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Kurume University Hospital, Kurume, Fukuoka, Japan